Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDG-16177
- Development stage
- Phase 1
- Lead developer
- Ildong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IDG-16177 is a potent, orally bioavailable small molecule agonist of G protein-coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (FFAR1), developed primarily for the treatment of type 2 diabetes mellitus. It acts by stimulating GPR40 on pancreatic β-cells, which enhances glucose-stimulated insulin secretion in a glucose-dependent manner. IDG-16177 has demonstrated higher potency and efficacy than fasiglifam (TAK-875) in preclinical studies, with favorable pharmacokinetic properties including high oral bioavailability across multiple species. Mechanistically, it stimulates both β-arrestin and gastrointestinal hormone pathways to promote insulin release and improve glucose tolerance. The drug is currently in phase I clinical trials for type 2 diabetes mellitus.
- Other names
- idg-16177idg16177idg 16177
02
Targets
FFAR1 (Free fatty acid receptor 1)
Beyond the preview
Go deeper on IDG-16177.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDG-16177.